Company: ARVN
Filing Date: 2025-10-06
Form Type: 8-K
Source: 0001628280-25-044212
Chunk: 2

Company: ARVINAS, INC.
Filing Date: 2025-10-06
Form: 8-K
Item: Item 8.01
Chunk 2
---
MC LRRK2 protein reductions of 86% with the 50 mg dose and 97% with the 200 mg dose.

• CSF Proteomics: In healthy volunteers treated with ARV-102 80 mg once daily for 14 days, unbiased proteomic analyses of CSF showed significant decreases in lysosomal pathway markers and neuroinflammatory microglial markers previously shown to be elevated in patients with Parkinson's disease harboring LRRK2 variants.

The Company believes these data highlight the potential PROTAC-mediated LRRK2 degradation, which supports the intensified development of ARV-102 in ongoing studies of patients with Parkinson’s disease, and future studies of patients with progressive supranuclear palsy. The Company plans to present initial data from a multiple dose cohort of the Phase 1 clinical trial of ARV-102 in patients with Parkinson’s disease (ARV-102-103) in 2026. Pending data from the multiple

dose cohort and investigational new drug clearance, the Company intends to initiate a Phase 1b clinical trial of ARV-102 in patients with progressive supranuclear palsy in the first half of 2026.

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements that involve substantial risks and uncertainties, including statements regarding the Company's belief that these data highlight the potential PROTAC-mediated LRRK2 degradation, which supports the intensified development of ARV-102 in ongoing studies of patients with Parkinson’s disease, and future studies of patients with progressive supranuclear palsy; the Company's plans to present initial data from a multiple dose cohort of the Phase 1 clinical trial of trial in patients with Parkinson’s disease (ARV-102-103), and the timing thereof; and the Company's intention, pending data from the multiple dose cohort and investigational new drug clearance, to initiate a Phase 1b trial in patients with progressive supranuclear palsy, and the timing thereof. All statements, other than statements of historical facts, contained in this Current Report on Form 8-K, including statements regarding the Company’s strategy, future operations, prospects, plans and objectives of management, are forward-looking statements. The words "believe," "intends," "plans," "potential,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions or expectations disclosed in its forward-looking statements, and you should not place undue reliance